BUZZ-Tempus AI rises after partnering with Daiichi Sankyo for cancer drug

Tempus Al

Tempus Al

TEM

0.00

** Shares of genetics-testing firm Tempus AI TEM.O rise 2% to $49.34 premarket

** Co says it partnered with Japan's Daiichi Sankyo to use AI to speedily develop a drug for cancer

** Deal centers on an antibody drug conjugate, a targeted treatment that delivers chemotherapy directly to tumour cells

** Tempus says it will use AI tools and large real-world patient data to find biomarkers – biological signals that show which patients may benefit

** Adds the companies will jointly build AI models to select patients for trials and better understand how different patients respond to the drug

** Financial terms of the partnership not disclosed

** TEM shares up ~75% in 2025


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.